Literature DB >> 34898873

Ventricular septal defect with pulmonary atresia: approaches, results, prognosticators and current status.

Ansh Garg1, Rajesh Sharma2.   

Abstract

Ventricular septal defect with pulmonary atresia and major aortopulmonary collateral arteries is a complex congenital cardiac anomaly with a wide spectrum of anatomical variations. Akin to the same, the management options are also very diverse ranging from aggressive single-stage repair with unifocalisation to surgical palliation and/or staged repair and also heart transplant. There is no consensus on the best management option. This review aims at highlighting the various surgical options and proposing a management pathway suited for the subcontinent patients. © Crown 2021.

Entities:  

Keywords:  Pulmonary arteries; Pulmonary atresia; Rehabilitation; Right ventricle to pulmonary artery connection

Year:  2021        PMID: 34898873      PMCID: PMC8630160          DOI: 10.1007/s12055-020-01133-6

Source DB:  PubMed          Journal:  Indian J Thorac Cardiovasc Surg        ISSN: 0970-9134


  25 in total

1.  Staged repair of pulmonary atresia with ventricular septal defect and major systemic to pulmonary artery collaterals.

Authors:  K S Iyer; R B Mee
Journal:  Ann Thorac Surg       Date:  1991-01       Impact factor: 4.330

2.  Pulmonary atresia with ventricular septal defects and major aortopulmonary collateral arteries: unifocalization brings no long-term benefits.

Authors:  Yves d'Udekem; Nelson Alphonso; Martin A Nørgaard; Andrew D Cochrane; Leeanne E Grigg; James L Wilkinson; Christian P Brizard
Journal:  J Thorac Cardiovasc Surg       Date:  2005-12       Impact factor: 5.209

3.  The enlargement of small pulmonary arteries by preliminary palliative operations.

Authors:  J W Kirklin; L M Bargeron; A D Pacifico
Journal:  Circulation       Date:  1977-10       Impact factor: 29.690

4.  Surgical algorithm and results for repair of pulmonary atresia with ventricular septal defect and major aortopulmonary collaterals.

Authors:  Richard D Mainwaring; William L Patrick; Stephen J Roth; Komal Kamra; Lisa Wise-Faberowski; Michal Palmon; Frank L Hanley
Journal:  J Thorac Cardiovasc Surg       Date:  2018-04-12       Impact factor: 5.209

5.  Coronary to pulmonary artery collaterals in patients with pulmonary atresia and ventricular septal defect.

Authors:  Z Amin; D B McElhinney; V M Reddy; P Moore; F L Hanley; D F Teitel
Journal:  Ann Thorac Surg       Date:  2000-07       Impact factor: 4.330

6.  Programmatic Approach to Management of Tetralogy of Fallot With Major Aortopulmonary Collateral Arteries: A 15-Year Experience With 458 Patients.

Authors:  Holly Bauser-Heaton; Alejandro Borquez; Brian Han; Michael Ladd; Ritu Asija; Laura Downey; Andrew Koth; Claudia A Algaze; Lisa Wise-Faberowski; Stanton B Perry; Andrew Shin; Lynn F Peng; Frank L Hanley; Doff B McElhinney
Journal:  Circ Cardiovasc Interv       Date:  2017-04       Impact factor: 6.546

7.  Pulmonary atresia with ventricular septal defects and major aortopulmonary collateral arteries.

Authors:  Suk-Won Song; Han Ki Park; Young-Hwan Park; Bum Koo Cho
Journal:  Circ J       Date:  2009-01-28       Impact factor: 2.993

8.  Staged repair of pulmonary atresia with ventricular septal defect and major aortopulmonary collateral arteries: experience with 104 patients.

Authors:  Anuja Gupta; Jonah Odim; Daniel Levi; Ruey-Kang Chang; Hillel Laks
Journal:  J Thorac Cardiovasc Surg       Date:  2003-12       Impact factor: 5.209

9.  Staged surgical management of pulmonary atresia with diminutive pulmonary arteries.

Authors:  C C Gill; D S Moodie; D C McGoon
Journal:  J Thorac Cardiovasc Surg       Date:  1977-03       Impact factor: 5.209

10.  Multistage pulmonary artery rehabilitation in patients with pulmonary atresia, ventricular septal defect and hypoplastic pulmonary artery.

Authors:  Qiuming Chen; Kai Ma; Zhongdong Hua; Keming Yang; Hao Zhang; Xu Wang; Xiaopeng Hu; Fuxia Yan; Jinping Liu; Sen Zhang; Lei Qi; Shoujun Li
Journal:  Eur J Cardiothorac Surg       Date:  2016-03-22       Impact factor: 4.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.